Author:
Asayama Masako,Fuse Nozomu,Yoshino Takayuki,Yano Tomonori,Tahara Makoto,Doi Toshihiko,Fujii Satoshi,Ohtsu Atsushi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference28 articles.
1. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68:227–232
2. Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 81:1351–1355
3. Machida N, Boku N, Onozawa Y et al (2009) Treatment of metastatic poorly differentiated neuroendocrine carcinoma (PDNEC) with irinotecan plus cisplatin. Eur J Cancer Supple 7: 397 (ECCO15-34th ESMO Multidisciplinary Congress, Abstr. P-6624)
4. Hainsworth J, Spigel DR, Litchy S, Greco A (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548–3554
5. Hou Z, Elasmar SA, Lozano R et al (2003) A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 22 (Abstr. 1508)
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献